[{"id":"e41df1b0-a381-4409-acf3-86d752328c66","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472933","created_at":"2026-03-28T01:36:46.537Z","updated_at":"2026-03-28T01:36:46.537Z","phase":"Phase 2","brief_title":"Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies","source_id_and_acronym":"NCT07472933","lead_sponsor":"West China Hospital","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Tevimbra (tislelizumab-jsgr)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2026-03-18"},{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"231092fb-00ef-4553-bd1a-e401bd09459d","acronym":"LITESPARK-016","url":"https://clinicaltrials.gov/study/NCT04976634","created_at":"2021-07-26T17:53:23.648Z","updated_at":"2025-02-25T15:19:12.763Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","source_id_and_acronym":"NCT04976634 - LITESPARK-016","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Welireg (belzutifan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 730","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 03/22/2027","primary_completion_date":" 03/22/2027","study_txt":" Completion: 03/22/2027","study_completion_date":" 03/22/2027","last_update_posted":"2025-02-12"},{"id":"56a60848-4dfa-45d9-a49c-7194c5f7a955","acronym":"","url":"https://clinicaltrials.gov/study/NCT06564623","created_at":"2025-02-25T15:09:15.826Z","updated_at":"2025-02-25T15:09:15.826Z","phase":"Phase 1","brief_title":"Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)","source_id_and_acronym":"NCT06564623","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Hiltonol (poly-ICLC)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-12"},{"id":"9518cf2f-a488-48b8-a437-c584bd916e0c","acronym":"Brightline-2","url":"https://clinicaltrials.gov/study/NCT05512377","created_at":"2022-08-23T14:55:35.585Z","updated_at":"2025-02-25T15:19:58.742Z","phase":"Phase 2","brief_title":"Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder","source_id_and_acronym":"NCT05512377 - Brightline-2","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 99","initiation":"Initiation: 12/13/2022","start_date":" 12/13/2022","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2025-02-11"},{"id":"e4341e18-0636-4930-ba0b-0c9da6c26d3f","acronym":"DESTINY-BTC01","url":"https://clinicaltrials.gov/study/NCT06467357","created_at":"2025-02-25T15:45:41.147Z","updated_at":"2025-02-25T15:45:41.147Z","phase":"Phase 3","brief_title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","source_id_and_acronym":"NCT06467357 - DESTINY-BTC01","lead_sponsor":"AstraZeneca","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 620","initiation":"Initiation: 08/12/2024","start_date":" 08/12/2024","primary_txt":" Primary completion: 06/12/2028","primary_completion_date":" 06/12/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2025-02-11"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2025-02-25T15:26:28.507Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-10"},{"id":"235d782d-2e73-4b08-9fbb-54173c4ba4b6","acronym":"HERBOT","url":"https://clinicaltrials.gov/study/NCT05749900","created_at":"2023-03-01T15:02:12.876Z","updated_at":"2025-02-25T16:46:38.516Z","phase":"Phase 1/2","brief_title":"First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)","source_id_and_acronym":"NCT05749900 - HERBOT","lead_sponsor":"Yonsei University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2025-02-05"},{"id":"142062db-36ca-4e14-9e8e-ac5f1782efb5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578444","created_at":"2021-01-18T21:51:12.506Z","updated_at":"2025-02-25T16:53:18.843Z","phase":"","brief_title":"An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT04578444","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ziihera (zanidatamab-hrii)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-04"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"1def5e25-f757-4960-ad8f-fdd1be50dd50","acronym":"","url":"https://clinicaltrials.gov/study/NCT03785873","created_at":"2021-01-18T18:43:16.171Z","updated_at":"2025-02-25T14:27:55.298Z","phase":"Phase 1/2","brief_title":"Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT03785873","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 11/15/2024","primary_completion_date":" 11/15/2024","study_txt":" Completion: 11/15/2024","study_completion_date":" 11/15/2024","last_update_posted":"2024-12-18"},{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"784231b9-195e-4cdb-8b0c-3f60c54cd03b","acronym":"KEYNOTE-098","url":"https://clinicaltrials.gov/study/NCT02443324","created_at":"2021-01-17T17:34:42.987Z","updated_at":"2025-02-25T16:14:44.151Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","source_id_and_acronym":"NCT02443324 - KEYNOTE-098","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2024-07-31"},{"id":"c3c05277-42e5-4669-bea5-688ad1660501","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001658","created_at":"2023-08-21T14:08:46.484Z","updated_at":"2025-02-25T16:19:01.820Z","phase":"Phase 2","brief_title":"Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers","source_id_and_acronym":"NCT06001658","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD163 • CD68","pipe":" | ","alterations":" ARG1 overexpression • CD163 expression","tags":["CD8 • CD163 • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARG1 overexpression • CD163 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 07/08/2024","start_date":" 07/08/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-25"},{"id":"6206800b-ada7-4d44-b7fb-032aa56563fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT06084481","created_at":"2023-10-16T15:12:52.682Z","updated_at":"2024-07-02T16:34:26.033Z","phase":"Phase 1","brief_title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","source_id_and_acronym":"NCT06084481","lead_sponsor":"AbbVie","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telisotuzumab adizutecan (ABBV-400)"],"overall_status":"Recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 11/09/2023","start_date":" 11/09/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-14"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"28ed5efa-c5b5-4262-aa3e-54b883b60ead","acronym":"ARTISTRY-3","url":"https://clinicaltrials.gov/study/NCT04592653","created_at":"2021-01-19T20:28:47.499Z","updated_at":"2024-07-02T16:34:37.223Z","phase":"Phase 1/2","brief_title":"Less Frequent IV Dosing \u0026 Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","source_id_and_acronym":"NCT04592653 - ARTISTRY-3","lead_sponsor":"Mural Oncology, Inc","biomarkers":" MSI • NCAM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemvaleukin alfa (ALKS 4230)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 09/30/2020","start_date":" 09/30/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-07"},{"id":"285e0fae-6b50-4026-b6af-15e5137223d2","acronym":"ZWI-ZW25-201","url":"https://clinicaltrials.gov/study/NCT03929666","created_at":"2021-01-18T19:21:37.373Z","updated_at":"2024-07-02T16:34:37.769Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","source_id_and_acronym":"NCT03929666 - ZWI-ZW25-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • KRAS • BRAF • NRAS • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-06-06"},{"id":"135a83dc-8c93-46d8-9a8a-d2365231d5e3","acronym":"HERIZON-BTC-01","url":"https://clinicaltrials.gov/study/NCT04466891","created_at":"2021-01-18T21:28:04.717Z","updated_at":"2024-07-02T16:35:00.002Z","phase":"Phase 2","brief_title":"A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers","source_id_and_acronym":"NCT04466891 - HERIZON-BTC-01","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 07/28/2023","primary_completion_date":" 07/28/2023","study_txt":" Completion: 10/31/2024","study_completion_date":" 10/31/2024","last_update_posted":"2024-05-30"},{"id":"cdacc270-2f12-47f1-ad69-ceb4bc5981ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337087","created_at":"2021-01-18T16:29:08.233Z","updated_at":"2024-07-02T16:35:02.682Z","phase":"Phase 1/2","brief_title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","source_id_and_acronym":"NCT03337087","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/02/2018","start_date":" 11/02/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2024-05-17"},{"id":"f1eb15be-99b0-4993-89d8-1f3e74e59506","acronym":"","url":"https://clinicaltrials.gov/study/NCT05297903","created_at":"2022-03-28T13:52:59.235Z","updated_at":"2024-07-02T16:35:05.357Z","phase":"Phase 2","brief_title":"XmAb20717 in Advanced Biliary Tract Cancers","source_id_and_acronym":"NCT05297903","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" FGFR2 • IDH1 • NTRK","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion","tags":["FGFR2 • IDH1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-07"},{"id":"87f0861a-71c2-4555-9071-1764face39ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04641871","created_at":"2021-08-24T14:53:56.048Z","updated_at":"2024-07-02T16:35:07.851Z","phase":"Phase 1","brief_title":"Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies","source_id_and_acronym":"NCT04641871","lead_sponsor":"Symphogen A/S","biomarkers":" FGFR2 • IDH1","pipe":" | ","alterations":" IDH1 mutation • FGFR2 mutation • FGFR2 fusion","tags":["FGFR2 • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • FGFR2 mutation • FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • S95018 • Sym021 • Sym022"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/12/2020","start_date":" 10/12/2020","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-24"},{"id":"56340f92-11bf-404d-bdf4-c92c67bb6993","acronym":"","url":"https://clinicaltrials.gov/study/NCT05001516","created_at":"2021-08-12T14:54:30.593Z","updated_at":"2024-07-02T16:35:09.043Z","phase":"Phase 1","brief_title":"Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors","source_id_and_acronym":"NCT05001516","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" MSI • CLDN18","pipe":" | ","alterations":" MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive","tags":["MSI • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tecotabart vedotin (LM-302)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/29/2021","start_date":" 12/29/2021","primary_txt":" Primary completion: 01/04/2024","primary_completion_date":" 01/04/2024","study_txt":" Completion: 01/04/2024","study_completion_date":" 01/04/2024","last_update_posted":"2024-04-17"}]